Brokerages expect Envista Holdings Co. (NYSE:NVST – Get Rating) to post $0.44 earnings per share (EPS) for the current fiscal quarter, Zacks reports. Six analysts have provided estimates for Envista’s earnings. The lowest EPS estimate is $0.40 and the highest is $0.47. Envista posted earnings per share of $0.54 during the same quarter last year, which would suggest a negative year over year growth rate of 18.5%. The business is expected to announce its next quarterly earnings report after the market closes on Monday, January 1st.
According to Zacks, analysts expect that Envista will report full-year earnings of $1.99 per share for the current year, with EPS estimates ranging from $1.86 to $2.05. For the next year, analysts forecast that the business will post earnings of $2.23 per share, with EPS estimates ranging from $2.11 to $2.31. Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Envista.
Envista (NYSE:NVST – Get Rating) last released its quarterly earnings results on Wednesday, February 9th. The company reported $0.46 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.42 by $0.04. The firm had revenue of $651.80 million during the quarter, compared to analyst estimates of $633.22 million. Envista had a return on equity of 8.96% and a net margin of 12.57%. During the same period in the previous year, the company posted $0.56 EPS.
In other Envista news, SVP Mischa Reis sold 6,056 shares of the stock in a transaction that occurred on Friday, February 11th. The stock was sold at an average price of $47.50, for a total transaction of $287,660.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Amir Aghdaei sold 10,538 shares of the stock in a transaction that occurred on Tuesday, March 29th. The stock was sold at an average price of $51.66, for a total value of $544,393.08. The disclosure for this sale can be found here. Insiders sold 155,488 shares of company stock worth $7,608,414 in the last 90 days. Company insiders own 0.82% of the company’s stock.
Hedge funds have recently modified their holdings of the business. First Horizon Advisors Inc. raised its holdings in shares of Envista by 357.5% during the third quarter. First Horizon Advisors Inc. now owns 398 shares of the company’s stock valued at $34,000 after acquiring an additional 311 shares during the last quarter. Dark Forest Capital Management LP raised its holdings in shares of Envista by 69.1% during the third quarter. Dark Forest Capital Management LP now owns 947 shares of the company’s stock valued at $40,000 after acquiring an additional 387 shares during the last quarter. Covestor Ltd acquired a new position in shares of Envista during the fourth quarter valued at approximately $43,000. Eagle Bay Advisors LLC raised its holdings in shares of Envista by 100.0% during the third quarter. Eagle Bay Advisors LLC now owns 1,800 shares of the company’s stock valued at $76,000 after acquiring an additional 900 shares during the last quarter. Finally, CWM LLC acquired a new position in shares of Envista during the fourth quarter valued at approximately $84,000.
Shares of NVST traded down $1.16 during trading hours on Tuesday, hitting $44.56. The company had a trading volume of 2,918,784 shares, compared to its average volume of 1,850,669. The company has a market capitalization of $7.25 billion, a PE ratio of 23.21, a price-to-earnings-growth ratio of 1.75 and a beta of 1.59. The company has a current ratio of 1.52, a quick ratio of 1.30 and a debt-to-equity ratio of 0.22. Envista has a one year low of $37.60 and a one year high of $52.03. The company’s fifty day moving average price is $47.50 and its two-hundred day moving average price is $43.93.
Envista Company Profile (Get Rating)
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, and markets dental products in the United States and internationally. The company operates in two segments, Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, prefabricated and custom-built prosthetics, and dental eye loupes to oral surgeons, prosthodontists, and periodontists under the brands, including Nobel Biocare, Alpha Bio Tec, Implant Direct, Logon, Nobel Procera, and Orascoptic; and brackets and wires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Damon, Ormco, Insignia, AOA, and Spark brands.
- Get a free copy of the StockNews.com research report on Envista (NVST)
- Institutional Buying Puts A Bottom In Manpower Group Inc
- Workhorse Johnson & Johnson Plows New All-Time Highs
- J.B. Hunt Transportation Services Fires On All Cylinders
- Fastenal Stock is Ready to Sprint Higher
- 3 No-Brainer Stocks to Buy with $1000
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.